The Patient Ratings and comments are gathered from our Patient Satisfaction Survey and displayed in their entirety.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
Activate Your Account with an access code or Create a New Account
David Miklos, M.D., Ph.D.
Blood and marrow transplant specialist, Hematologist, Medical oncologist
Associate Professor of Medicine (Blood and Marrow Transplantation) at the Stanford University Medical Center
Bio:
I am a physician-scientist who has established a human translational research group that fosters the development of both laboratory immunologists, and clinical translational researchers. Allogeneic hematopoietic cell transplantation (alloHCT) cures blood cancer via beneficial graft-v-tumor immunity. Our overall research goal is to augment GVT while preventing dertimental graft versus host disease (GVHD). The Miklos lab pioneered protein microarray technologies to disciiver clinically relevant allogeneic antibodies, especially those targeting H-Y antigens following sex mismatched transplantation. Our discovery that allogeneic HY antibodies develop in association with chronic GVHD revealed a critical B cell role in chronic GVHD pathogenesis and our clinical trials established cGVHD therapeutic benefits using anti-B cell drugs rituximab and ibrutinib. We developed high-throughput sequencing of the B and T cell immune receptor thereby enabling: 1) lymphoid disease quantification, 2) detailed B and T cell donor reconstitution kinetics, and 3) clonal analysis of antigen specific responses following allo-HCT.
Immunotherapy is revolutionizing cancer treatment and as the Stanford Clinical Cancer Cell Therapy program develops and evaluates the most promising cutting-edge cell therapies for cancer patients on a variety of clinical trials. Chimeric Antigen T Cell (CAR-T) therapy targets the patient's T lymphocytes to attack their cancer by infecting their own T cells to express chimeric antigen receptor (CAR) proteins that target and kill cancer cell expressing surface proteins. Thus far, the most successful CAR-T have targeted B cell antigen CD19, and ongoing trials are treating patients with relapsed/refractory Diffuse Large B Cell Lymphoma (DLBCL) using this CAR19 therapy.
Immunotherapy is revolutionizing cancer treatment and as the Stanford Clinical Cancer Cell Therapy program develops and evaluates the most promising cutting-edge cell therapies for cancer patients on a variety of clinical trials. Chimeric Antigen T Cell (CAR-T) therapy targets the patient's T lymphocytes to attack their cancer by infecting their own T cells to express chimeric antigen receptor (CAR) proteins that target and kill cancer cell expressing surface proteins. Thus far, the most successful CAR-T have targeted B cell antigen CD19, and ongoing trials are treating patients with relapsed/refractory Diffuse Large B Cell Lymphoma (DLBCL) using this CAR19 therapy.
- 875 Blake Wilbur Drive
- Clinic E, 1st Floor
- Palo Alto , CA 94304
- Phone: 650-723-0822
- 875 Blake Wilbur Drive
- Clinic F
- Palo Alto , CA 94304
- Phone: 650-498-6000
- 875 Blake Wilbur Drive
- Palo Alto , CA 94304
- Phone: 650-498-6000
Practice Areas
- Hairy Cell Leukemia
- Hemophilia
- Immune Thrombocytopenic Purpura
- Immunophenotyping
- Immunotherapy (Biological Therapy)
- Leukemia
- Lumbar Puncture (Spinal Tap)
- Multiple Myeloma
- Myelodysplastic Syndromes (MDS)
- Myelofibrosis (Agnogenic Myeloid Metaplasia or AMM)
- Myeloproliferative Neoplasms
- Polycythemia Vera
- Thrombosis
Professional Education
- Fellowship: Dana Farber Cancer Institute Hematology Oncology Fellowship (2001) MA
- Residency: Brigham and Women's Hospital Harvard Medical School (1998) MA
- Internship: Brigham and Women's Hospital Harvard Medical School (1996) MA
- Medical Education: Yale University (1995) CT
- B.S., University of Notre Dame (1987)
- M.D., Yale University Medical School (1995)
- Ph.D., Yale University, Genetics (1995)
Honors & Awards
- Alpha Omega Alpha, Yale Medical School (1995)
- Clinical Investigator Training Program Scholar, Harvard Medical School (2001-2003)
- Medical Scientist Training Fellow, NIH (1993-1995)
- Phi Betta Kappa, University of Notre Dame (1987)
- Predoctoral Fellow, Howard Hughes Medical Institute (1989-1993)
Administrative Appointments
- Clinical Director Cancer Cell Therapy, Stanford University (2016 - Present)
- Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease, NIH (2004 - Present)
- Medical Director of Stanford Cellular Therapeutics and Transplantation Laboratory, Stanford University (2011 - Present)
Publications
-
Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors
Miklos, D. B., Kim, H. T., Zorn, E., Hochberg, E. P., Guo, L. X., Mattes-Ritz, A., … Ritz, J. (2004). Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. BLOOD, 103(1), 353–359. -
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission
Miklos, D. B., Kim, H. T., Miller, K. H., Guo, L. X., Zorn, E., Lee, S. J., … Ritz, J. (2005). Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. BLOOD, 105(7), 2973–2978. -
Renal pathology in hematopoietic cell transplantation recipients
Troxell, M. L., Pilapil, M., Miklos, D. B., Higgins, J. P., & Kambham, N. (2008). Renal pathology in hematopoietic cell transplantation recipients. MODERN PATHOLOGY, 21(4), 396–406. -
H-Y antibody development associates with acute rejection in female patients with male kidney transplants
Tan, J. C., Wadia, P. P., Coram, M., Grumet, F. C., Kambham, N., Miller, K., … Miklos, D. B. (2008). H-Y antibody development associates with acute rejection in female patients with male kidney transplants. TRANSPLANTATION, 86(1), 75–81.
-
Identifying compartment-specific non-HLA targets after renal transplantation by integrating transcriptome and "antibodyome'' measures
Li, L., Wadia, P., Chen, R., Kambham, N., Naesens, M., Sigdel, T. K., … Butte, A. J. (2009). Identifying compartment-specific non-HLA targets after renal transplantation by integrating transcriptome and "antibodyome'' measures. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 106(11), 4148–4153.
-
TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors
Kohrt, H. E., Turnbull, B. B., Heydari, K., Shizuru, J. A., Laport, G. G., Miklos, D. B., … Lowsky, R. (2009). TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. BLOOD, 114(5), 1099–1109.
-
Antibodies specifically target AML antigen NuSAP1 after allogeneic bone marrow transplantation
Wadia, P. P., Coram, M., Armstrong, R. J., Mindrinos, M., Butte, A. J., & Miklos, D. B. (2010). Antibodies specifically target AML antigen NuSAP1 after allogeneic bone marrow transplantation. BLOOD, 115(10), 2077–2087.
-
Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma
Arai, S., Letsinger, R., Wong, R. M., Johnston, L. J., Laport, G. G., Lowsky, R., … Horning, S. J. (2010). Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 16(8), 1145–1154.
-
Rituximab in hematopoietic cell transplantation
Arai, S., & Miklos, D. B. (2010). Rituximab in hematopoietic cell transplantation. EXPERT OPINION ON BIOLOGICAL THERAPY, 10(6), 971–982.
-
Individual Variation in the Germline Ig Gene Repertoire Inferred from Variable Region Gene Rearrangements
Boyd, S. D., Gaeta, B. A., Jackson, K. J., Fire, A. Z., Marshall, E. L., Merker, J. D., … Collins, A. M. (2010). Individual Variation in the Germline Ig Gene Repertoire Inferred from Variable Region Gene Rearrangements. JOURNAL OF IMMUNOLOGY, 184(12), 6986–6992.
-
Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY
Naik, S., Wong, R., Arai, S., Brown, J., Laport, G., Lowsky, R., … Johnston, L. (2011). Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. BONE MARROW TRANSPLANTATION, 46(2), 192–199.
-
Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia
Jones, C. D., Arai, S., Lowsky, R., Tyan, D. B., Zehnder, J. L., & Miklos, D. B. (2010). Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 150(5), 637–639.
-
Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation.
Müller, A. M. S., Linderman, J. A., Florek, M., Miklos, D., & Shizuru, J. A. (2010). Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation. Proceedings of the National Academy of Sciences of the United States of America, 107(33), 14721–14726.
-
Protein Microarrays Discover Angiotensinogen and PRKRIP1 as Novel Targets for Autoantibodies in Chronic Renal Disease
Butte, A. J., Sigdel, T. K., Wadia, P. P., Miklos, D. B., & Sarwal, M. M. (2011). Protein Microarrays Discover Angiotensinogen and PRKRIP1 as Novel Targets for Autoantibodies in Chronic Renal Disease. MOLECULAR & CELLULAR PROTEOMICS, 10(3).
-
Clonally identical Hodgkin's disease develops after allogeneic hematopoietic cell transplant for CLL
Tseng, D., Jones, C. D., Anderson, M., Warnke, R., Zehnder, J. L., & Miklos, D. B. (2011). Clonally identical Hodgkin's disease develops after allogeneic hematopoietic cell transplant for CLL. BONE MARROW TRANSPLANTATION, 46(12), 1576–1578.
-
Recombinant antigen microarrays for serum/plasma antibody detection.
Wadia, P. P., Sahaf, B., & Miklos, D. B. (2011). Recombinant antigen microarrays for serum/plasma antibody detection. Methods in Molecular Biology (Clifton, N.J.), 723, 81–104.
-
B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies
Winer, D. A., Winer, S., Shen, L., Wadia, P. P., Yantha, J., Paltser, G., … Engleman, E. G. (2011). B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. NATURE MEDICINE, 17(5), 610–U134.
-
Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation
Johnston, L., Florek, M., Armstrong, R., McCune, J. S., Arai, S., Brown, J., … Negrin, R. (2012). Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. BONE MARROW TRANSPLANTATION, 47(4), 581–588.
-
Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation
Laport, G. G., Sheehan, K., Baker, J., Armstrong, R., Wong, R. M., Lowsky, R., … Negrin, R. S. (2011). Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(11), 1679–1687.
-
Combined CD4 T-Cell and Antibody Response to Human Minor Histocompatibility Antigen DBY After Allogeneic Stem-Cell Transplantation
Porcheray, F., Miklos, D. B., Floyd, B. H., Sarantopoulos, S., Bellucci, R., Soiffer, R. J., … Zorn, E. (2011). Combined CD4 T-Cell and Antibody Response to Human Minor Histocompatibility Antigen DBY After Allogeneic Stem-Cell Transplantation. TRANSPLANTATION, 92(3), 359–365.
-
A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies
Chen, G. L., Arai, S., Flowers, M. E. D., Otani, J. M., Qiu, J., Cheng, E. C., … Miklos, D. B. (2011). A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. BLOOD, 118(15), 4070–4078.
-
High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment
Logan, A. C., Gao, H., Wang, C., Sahaf, B., Jones, C. D., Marshall, E. L., … Miklos, D. B. (2011). High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 108(52), 21194–21199.
-
Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence
Arai, S., Sahaf, B., Narasimhan, B., Chen, G. L., Jones, C. D., Lowsky, R., … Miklos, D. B. (2012). Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. BLOOD, 119(25), 6145–6154.
-
H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease
Sahaf, B., Yang, Y., Arai, S., Herzenberg, L. A., Herzenberg, L. A., & Miklos, D. B. (2013). H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 110(8), 3005–3010.
-
Minimal residual disease quantification using consensus primers and high- throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia
Logan, A. C., Zhang, B., Narasimhan, B., Carlton, V., Zheng, J., Moorhead, M., … Miklos, D. B. (2013). Minimal residual disease quantification using consensus primers and high- throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. LEUKEMIA, 27(8), 1659–1665.
-
A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease.
Meyer, E. H., Hsu, A. R., Liliental, J., Löhr, A., Florek, M., Zehnder, J. L., … Negrin, R. S. (2013). A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease. Blood, 121(24), 4955–4962.
-
The Outcomes of Family Haploidentical Hematopoietic Stem Cell Transplantation in Hematologic Malignancies Are Not Associated with Patient Age
Dong, L., Wu, T., Gao, Z.-Y., Zhang, M.-J., Kan, F., Spellman, S. R., … Lee, S. J. (2011). The Outcomes of Family Haploidentical Hematopoietic Stem Cell Transplantation in Hematologic Malignancies Are Not Associated with Patient Age. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(8), 1205–1213.
-
Birth Order and Transplantation Outcome in HLA-Identical Sibling Stem Cell Transplantation: An Analysis on Behalf of the Center for International Blood and Marrow Transplantation
Dobbelstein, C., Ahn, K. W., Haagenson, M., Hale, G. A., Van Rood, J. J., Miklos, D., … Lee, S. J. (2013). Birth Order and Transplantation Outcome in HLA-Identical Sibling Stem Cell Transplantation: An Analysis on Behalf of the Center for International Blood and Marrow Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19(5), 741–745.
-
Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker working group report
Schultz, K. R., Miklos, D. B., Fowler, D., Cooke, K., Shizuru, J., Zorn, E., … Pavletic, S. Z. (2006). Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker working group report. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 12(2), 126–137.
-
Rituximab for steroid-refractory chronic graft-versus-host disease
Cutler, C., Miklos, D., Kim, H. T., Treister, N., Woo, S.-B., Bienfang, D., … Alyea, E. (2006). Rituximab for steroid-refractory chronic graft-versus-host disease. BLOOD, 108(2), 756–762.
-
H-Y antibody titers are increased in unexplained secondary recurrent miscarriage patients and associated with low male : female ratio in subsequent live births
Nielsen, H. S., Wu, F., Aghai, Z., Steffensen, R., van Halteren, A. G., Spierings, E., … Goulmy, E. (2010). H-Y antibody titers are increased in unexplained secondary recurrent miscarriage patients and associated with low male : female ratio in subsequent live births. HUMAN REPRODUCTION, 25(11), 2745–2752.
-
Humoral Immunity to Cytomegalovirus and Chronic Graft-Versus-Host Disease
Namboodiri, A. M., Nietert, P. J., Wadia, P. P., Miklos, D. B., & Pandey, J. P. (2012). Humoral Immunity to Cytomegalovirus and Chronic Graft-Versus-Host Disease. VIRAL IMMUNOLOGY, 25(4), 338–340.
-
Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors
Shaw, P. J., Kan, F., Ahn, K. W., Spellman, S. R., Aljurf, M., Ayas, M., … Pulsipher, M. A. (2010). Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. BLOOD, 116(19), 4007–4015.
-
B Cells and Transplantation: An Educational Resource
Small, T. N., Robinson, W. H., & Miklos, D. B. (2009). B Cells and Transplantation: An Educational Resource. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 15(1), 104–113.
-
Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.
Benjamin, J., Chhabra, S., Kohrt, H. E., Lavori, P., Laport, G. G., Arai, S., … Lowsky, R. (2014). Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms. Biology of Blood and Marrow Transplantation , 20(6), 837–843.
-
Clinical impact of H-Y alloimmunity.
Popli, R., Sahaf, B., Nakasone, H., Lee, J. Y. Y., & Miklos, D. B. (2014). Clinical impact of H-Y alloimmunity. Immunologic Research, 58(2-3), 249–258.
-
Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival.
Logan, A. C., Vashi, N., Faham, M., Carlton, V., Kong, K., Buño, I., … Miklos, D. B. (2014). Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival. Biology of Blood and Marrow Transplantation , 20(9), 1307–13.
-
Risk associations between HLA-DPB1 T-cell epitope matching and outcome of unrelated hematopoietic cell transplantation are independent of HLA-DPA1.
Fleischhauer, K., Fernandez-Viña, M. A., Wang, T., Haagenson, M., Battiwalla, M., Baxter-Lowe, L. A., … Spellman, S. R. (2014). Risk associations between HLA-DPB1 T-cell epitope matching and outcome of unrelated hematopoietic cell transplantation are independent of HLA-DPA1. Bone Marrow Transplantation, 49(9), 1176–1183.
-
A Reduced-Toxicity Regimen Is Associated with Durable Engraftment and Clinical Cure of Nonmalignant Genetic Diseases among Children Undergoing Blood and Marrow Transplantation with an HLA-Matched Related Donor.
Mahadeo, K. M., Weinberg, K. I., Abdel-Azim, H., Miklos, D. B., Killen, R., Kohn, D., … Kapoor, N. (2015). A Reduced-Toxicity Regimen Is Associated with Durable Engraftment and Clinical Cure of Nonmalignant Genetic Diseases among Children Undergoing Blood and Marrow Transplantation with an HLA-Matched Related Donor. Biology of Blood and Marrow Transplantation , 21(3), 440–444.
-
Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans
Nakasone, H., Tian, L., Sahaf, B., Kawase, T., Schoenrock, K., Perloff, S., … Miklos, D. B. (2015). Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans. BLOOD, 125(20), 3193–3201.
-
ABO Mismatch Is Associated with Increased Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation
Logan, A. C., Wang, Z., Alimoghaddam, K., Wong, R. M., Lai, T., Negrin, R. S., … Miklos, D. B. (2015). ABO Mismatch Is Associated with Increased Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 21(4), 746–754.
-
Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing.
Kurtz, D. M., Green, M. R., Bratman, S. V., Scherer, F., Liu, C. L., Kunder, C. A., … Alizadeh, A. A. (2015). Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood, 125(24), 3679–3687.
-
Therapeutic benefits targeting B-cells in chronic graft-versus-host disease
Nakasone, H., Sahaf, B., & Miklos, D. B. (2015). Therapeutic benefits targeting B-cells in chronic graft-versus-host disease. INTERNATIONAL JOURNAL OF HEMATOLOGY, 101(5), 438–451.
-
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report
Paczesny, S., Hakim, F. T., Pidala, J., Cooke, K. R., Lathrop, J., Griffith, L. M., … Schultz, K. R. (2015). National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 21(5), 780–792.
-
Red blood cell transfusions are associated with HLA class I but not H-Y alloantibodies in children with sickle cell disease.
Nickel, R. S., Hendrickson, J. E., Yee, M. M., Bray, R. A., Gebel, H. M., Kean, L. S., … Horan, J. T. (2015). Red blood cell transfusions are associated with HLA class I but not H-Y alloantibodies in children with sickle cell disease. British Journal of Haematology, 170(2), 247–256.
-
Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy.
Nakasone, H., Remberger, M., Tian, L., Brodin, P., Sahaf, B., Wu, F., … Meyer, E. (2015). Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy. Haematologica, 100(11), 1477–1485.
-
Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning
Rezvani, A. R., Kanate, A. S., Efron, B., Chhabra, S., Kohrt, H. E., Shizuru, J. A., … Lowsky, R. (2015). Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning. BONE MARROW TRANSPLANTATION, 50(10), 1286–1292.
-
A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation.
Arai, S., Pidala, J., Pusic, I., Chai, X., Jaglowski, S., Khera, N., … Flowers, M. E. D. (2016). A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. Clinical Cancer Research , 22(2), 319–327.
-
High-throughput allogeneic antibody detection using protein microarrays
Paul, J., Sahaf, B., Perloff, S., Schoenrock, K., Wu, F., Nakasone, H., … Miklos, D. (2016). High-throughput allogeneic antibody detection using protein microarrays. JOURNAL OF IMMUNOLOGICAL METHODS, 432, 57–64.
-
A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease
Meyer, E. H., Hsu, A. R., Liliental, J., Loehr, A., Florek, M., Zehnder, J. L., … Negrin, R. S. (2013). A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease. BLOOD, 121(24), 4955–4962.
-
Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation
Mueller, A. M. S., Linderman, J. A., Florek, M., Miklos, D., & Shizuru, J. A. (2010). Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 107(33), 14721–14726.
-
Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.
Ryan, C. E., Sahaf, B., Logan, A. C., O'Brien, S., Byrd, J. C., Hillmen, P., … Miklos, D. B. (2016). Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood.
-
The Biology of Chronic Graft-Versus-Host Disease: a Task Force Report From the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease.
Cooke, K. R., Luznik, L., Sarantopoulos, S., Hakim, F. T., Jagasia, M., Fowler, D. H., … Blazar, B. R. (2016). The Biology of Chronic Graft-Versus-Host Disease: a Task Force Report From the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation .
-
Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-ß production.
Du, J., Paz, K., Flynn, R., Vulic, A., Robinson, T. M., Lineburg, K. E., … Blazar, B. R. (2017). Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-ß production. Blood.
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Patient Comments
Patients comments are gathered from our Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
SHC Patient, May 2017
Dr. Miklos is exceptional.
SHC Patient, Feb 2017
Dr. Miklos good job he cares so much about his treatment for you and how you are doing.
SHC Patient, Feb 2017
The doctor spent a lot of time with us explaining my care, his team also spent a lot of time with us explaining treatment.
SHC Patient, Jan 2017
I fully trust Dr. Miklos with all my medical concerns. He's very caring & welcomed me & my family well. His nursing assistant is also great! Her name is Sandy Burgess & she always took care of all my concerns.
SHC Patient, Dec 2016
Dr. Miklos is very knowledgable & empathetic. Always available & responsive.
SHC Patient, Dec 2016
Huge fan of Dr Miklos!
SHC Patient, Dec 2016
Dr. Mikios is a wonderful doctor and a kind man.
SHC Patient, Sep 2016
Excellent.
SHC Patient, Aug 2016
Dr. Miklos is a star doctor. He genuinely cares about me and spends generous amount of time with me and my family. I got educated on my illness and I am very thankful to Dr. Miklos and his team.
SHC Patient, Aug 2016
Miklos provided a thorough amount of hand written info - But I was overwhelmed by the depth and technical aspects of what he described.
SHC Patient, May 2016
Dr. Miklos is the best! I feel very grateful to have him as my doctor!
SHC Patient, May 2016
Dr. Mikios is my hero. I thank him for taking me through the transplant and the following care.
SHC Patient, Nov 2015
I have just recently recommended Dr. Miklos.
SHC Patient, Aug 2015
They were great. Spoke clearly and spoke my language. They even made a visual to clarify it.
SHC Patient, May 2015
Dr. Miklos spent a lot of time with me and answered all my questions.
SHC Patient, May 2015
Dr. Miklos & the entire team was amazing the total care I received was truly wonderful.
SHC Patient, May 2015
Amazing care provided by Dr. Miklos. Lots of good information.
SHC Patient, Apr 2015
Dr. Miklos is wonderful, approachable and thorough.
SHC Patient, Mar 2015
One time I had a concern which really scared me when the dr. just say it is what it is and I felt like I'm just a number in a study and I just wondered how serious my illness (life) is in this study or if I'm just a number.
SHC Patient, Feb 2015
Dr. Miklos is amazing.
SHC Patient, Oct 2014
Good.
SHC Patient, Sep 2014
Dr. Miklos always answers any questions I have and has always given me the best care.
SHC Patient, Apr 2014
Dr. Miklos from thy 1st time I met him to my last visit I could have a more understanding, knowledgeable doctor ever. He is outstanding.
SHC Patient, Mar 2014
Dr. Miklos saved my life. Because of him I get to watch my daughter grow.
SHC Patient, May 2017
Dr. Miklos is exceptional.
SHC Patient, Feb 2017
Dr. Miklos good job he cares so much about his treatment for you and how you are doing.
SHC Patient, Feb 2017
The doctor spent a lot of time with us explaining my care, his team also spent a lot of time with us explaining treatment.
SHC Patient, Jan 2017
I fully trust Dr. Miklos with all my medical concerns. He's very caring & welcomed me & my family well. His nursing assistant is also great! Her name is Sandy Burgess & she always took care of all my concerns.
SHC Patient, Dec 2016
Dr. Miklos is very knowledgable & empathetic. Always available & responsive.
SHC Patient, Dec 2016
Huge fan of Dr Miklos!
SHC Patient, Dec 2016
Dr. Mikios is a wonderful doctor and a kind man.
SHC Patient, Sep 2016
Excellent.
SHC Patient, Aug 2016
Dr. Miklos is a star doctor. He genuinely cares about me and spends generous amount of time with me and my family. I got educated on my illness and I am very thankful to Dr. Miklos and his team.
SHC Patient, Aug 2016
Miklos provided a thorough amount of hand written info - But I was overwhelmed by the depth and technical aspects of what he described.
SHC Patient, May 2016
Dr. Miklos is the best! I feel very grateful to have him as my doctor!
SHC Patient, May 2016
Dr. Mikios is my hero. I thank him for taking me through the transplant and the following care.
View All 24 Patient Comments »